Year: 2015
Type: review
Abstract: Pediatric acute myeloid leukemia (AML) represents 15%-20% of all pediatric acute leukemias. Survival rates have increased over the past few decades to ~70%, due to improved supportive care, optimized risk stratification and intensified chemotherapy. In most children, AML presents as a de novo entity, but in a minority, it is a secondary malignancy. The diagnostic classification of pediatric AML includes a combination of morphology, cytochemistry, immunophenotyping and molecular genetics. Outcome is mainly dependent on the initial response to treatment and molecular and cytogenetic aberrations. Treatment consists of a combination of intensive anthracycline- and cytarabine-containing chemotherapy and stem cell transplantation in selected genetic high-risk cases or slow responders. In general, ~30% of all pediatric AML patients will suffer from relapse, whereas 5%-10% of the patients will die due to disease complications or the side-effects of the treatment. Targeted therapy may enhance anti-leukemic efficacy and minimize treatment-related morbidity and mortality, but requires detailed knowledge of the genetic abnormalities and aberrant pathways involved in leukemogenesis. These efforts towards future personalized therapy in a rare disease, such as pediatric AML, require intensive international collaboration in order to enhance the survival rates of pediatric AML, while aiming to reduce long-term toxicity.
Source: Journal of Clinical Medicine
DOI: 10.3390/jcm4010127
Institution: Erasmus MC - Sophia Children’s Hospital
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Keywords: pediatric acute myeloid leukemia, secondary malignancies, risk stratification, chromosomal abnormalities, molecular genetics, immunophenotyping, cytochemistry, anthracycline chemotherapy, cytarabine, stem cell transplantation, relapse, targeted therapy, leukemogenesis, treatment toxicity, personalized treatment
Open Access status: gold
Estimated APC paid: $3,137
OpenAlex ID: W2002187983
